attenu
salmonella
typhimurium
select
transgen
vehicl
develop
live
mucos
vaccin
transmiss
gastroenter
viru
tgev
kb
dna
fragment
encod
ntermin
domain
glycoprotein
tgev
amplifi
rtpcr
clone
eukaryot
express
vector
recombin
plasmid
pvax
transform
electropor
attenu
typhimurium
express
translat
pvax
deliv
recombin
typhimurium
pvax
detect
vitro
vivo
respect
balbc
mice
inocul
oral
pvax
differ
dosag
bacterium
safe
mice
dosag
cfu
eventu
elimin
spleen
liver
week
postimmun
mice
immun
differ
dosag
pvax
elicit
specif
antitgev
local
mucos
humor
respons
measur
indirect
elisa
assay
moreov
immunogen
dna
vaccin
highli
depend
dosag
attenu
bacteria
use
oral
administr
cfu
dosag
group
show
higher
antibodi
respons
cfu
cfu
dosag
group
week
postimmun
result
indic
attenu
typhimurium
could
use
deliveri
vector
oral
immun
tgev
dna
vaccin
transmiss
gastroenter
tge
caus
seriou
intestin
infecti
diseas
swine
especi
sever
newborn
pig
less
two
week
old
result
nearli
mortal
caus
agent
transmiss
gastroenter
viru
tgev
belong
coronaviru
posit
singlestrand
rna
kb
consist
three
major
structur
protein
phosphoryl
nucleoprotein
n
two
glycoprotein
membran
spike
protein
envelop
protein
highli
glycosyl
mediat
bind
tgev
cellular
receptor
porcin
aminopeptidas
n
papn
major
induc
tgevneutr
antibodi
protein
use
mainli
induct
protect
immun
tgev
four
major
antigen
site
b
c
defin
aminotermin
domain
earlier
studi
shown
intact
globular
ntermin
half
protein
suffici
achiev
protect
immun
respons
equival
induc
full
protein
tgev
infect
villou
enterocyt
caus
local
infect
intestin
tract
result
villou
atrophi
consequ
malabsorpt
diarrhea
protect
suckl
piglet
tgev
infect
requir
induct
secretori
immunoglobulin
siga
milk
especi
colostrum
typic
igaproduc
plasma
cell
mammari
gland
pregnant
sow
origin
gutassoci
lymphoid
tissu
galt
activ
differ
antigen
compon
thu
new
develop
focus
product
deliveri
protein
oral
immun
sever
system
use
express
fulllength
truncat
tgev
protein
salmonella
lactobacillu
casei
plant
howev
express
level
antigen
protein
transgen
plant
gener
low
lose
bioactiv
due
degrad
stomach
acid
prokaryot
express
antigen
protein
bacteri
greatli
affect
immunogen
lack
glycosyl
posttransl
modif
forement
easi
effect
oral
vaccin
suitabl
protect
tgev
infect
highli
need
livestock
farm
recent
year
attenu
gramposit
gramneg
intracellular
bacteria
salmonella
shigella
listeria
use
carrier
effici
deliveri
either
dna
vaccin
vaccin
antigen
oral
immun
strategi
allow
administr
dna
vaccin
via
mucos
surfac
well
deliveri
plasmid
dna
directli
profession
antigen
present
cell
apc
elicit
strong
humor
cellular
respons
pathogen
particular
attenu
salmonella
typhimurium
typhimurium
use
deliv
dna
vaccin
encod
immunogen
pathogen
microorgan
includ
hiv
hbv
hsv
ndv
ibdv
prrsv
toxoplasma
gondii
howev
use
typhimurium
dna
vaccin
vector
tgev
almost
report
studi
use
attenu
intracellular
bacteria
attenu
typhimurium
carrier
deliveri
dna
vaccin
encod
ntermin
half
tgev
glycoprotein
data
indic
orogastr
intub
recombin
typhimurium
could
induc
specif
immun
respons
tgev
femal
balbc
mice
six
week
old
g
purchas
chengdu
institut
biolog
product
chengdu
china
maintain
anim
hold
laboratori
control
condit
temperatur
c
humid
free
access
standard
mous
diet
water
viral
rna
extract
tgevinfect
st
cell
use
mini
best
viral
rnadna
extract
kit
takara
kb
dna
fragment
encod
ntermin
glycoprotein
amplifi
viru
genom
rna
rtpcr
use
primer
forward
revers
respect
introduc
hindiii
bamhi
restrict
site
end
primer
amplifi
dna
fragment
tgev
gene
clone
vector
takara
sequenc
gene
fragment
releas
plasmid
hindiii
bamhi
digest
ligat
vector
cut
enzym
result
plasmid
name
pvax
sixwel
tissu
cultur
plate
costar
seed
cell
monolay
confluent
cell
transient
transfect
plasmid
pvax
empti
plasmid
use
lipofectamin
invitrogen
thirtytwo
hour
transfect
cell
wash
phosphatebufferedsalin
pb
fix
icecold
methanolaceton
c
min
wash
pb
dilut
primari
secondari
antibodi
incub
c
h
respect
primari
antibodi
antiserum
pig
tgev
kindli
provid
research
li
feng
harbin
veterinari
research
institut
china
secondari
antibodi
fitcconjugatedrabbitantipig
igg
sigma
purifi
plasmid
pvax
control
vector
transform
typhimurium
compet
cell
electropor
kv
f
posit
transform
select
lb
agar
contain
gml
kanamycin
verifi
pcr
amplif
digest
restrict
enzym
salmonella
strain
contain
plasmid
pvax
name
strain
pvax
strain
pvax
respect
twelveweekold
balbc
mice
sacrif
cervic
disloc
periton
caviti
inject
ml
rpmi
medium
gentl
abdomin
massag
maximum
amount
fluid
collect
periton
exud
cell
separ
centrifug
resuspend
ml
rpmi
medium
isol
periton
macrophag
allow
adher
h
sixwel
tissu
cultur
plate
costar
antibioticfre
medium
time
noadher
cell
remov
gentli
wash
plate
two
time
antibioticfre
medium
adher
cell
infect
recombin
typhimurium
strain
pvax
pvax
multipl
infect
moi
min
incub
c
infect
cell
wash
pb
incub
fresh
rpmi
contain
fetal
bovin
serum
fb
gml
gentamicin
h
medium
remov
replac
fresh
rpmi
contain
fb
gml
tetracyclin
h
infect
express
gene
detect
indirect
immunofluoresc
assay
ifa
sixweekold
mice
inocul
intragastr
cfu
pvax
control
mice
given
dosag
pvax
three
day
immun
payer
patch
remov
three
mice
pool
cellular
rna
isol
homogen
payer
patch
trizol
takara
accord
manufactur
instruct
transcript
tgev
gene
payer
patch
analyz
rtpcr
use
specif
primer
forward
ttaattttcaaa
revers
contain
b
c
site
gene
bp
length
mice
specif
primer
forward
acag
revers
amplifi
fragment
length
bp
use
qualiti
control
typhimurium
strain
pvax
cultur
condit
describ
previous
bacteri
cell
collect
centrifug
g
min
resuspend
pb
contain
sodium
bicarbon
mv
expect
cell
popul
determin
plate
serial
dilut
lb
agar
plate
three
group
sixweekold
balbc
mice
eight
mice
group
inocul
intragastr
use
gavag
needl
pvax
dosag
cfu
boost
dosag
two
week
later
immun
mice
monitor
daili
clinic
chang
two
mice
group
sacrif
everi
week
postimmun
spleen
liver
collect
homogen
ml
pb
contain
triton
vv
bacteri
count
determin
plate
l
homogen
spleen
liver
sampl
lb
agar
plate
contain
gml
kanamycin
bacteria
coloni
pick
randomli
pcr
identif
tgev
gene
digest
restrict
enzym
sixweekold
balbc
mice
randomli
divid
five
group
consist
twenti
mice
immun
three
time
two
week
interv
mice
depriv
food
water
h
oral
immun
mice
group
b
c
inocul
intragastr
pvax
differ
dosag
cfu
per
mous
respect
mice
group
inocul
intragastr
control
strain
pvax
cfu
per
mous
group
e
mice
receiv
pb
neg
control
three
mice
group
sacrif
sera
intestin
lavag
collect
week
primari
immun
blood
obtain
submaxillari
sinu
mice
sera
prepar
store
c
prior
analysi
prepar
intestin
fluid
cm
section
small
intestin
remov
mous
cut
piec
wash
ml
pb
contain
mmoll
phenylmethylsulfonyl
fluorid
mmoll
edta
pbspe
sampl
centrifug
g
min
remov
cellular
debri
supernat
freezedri
use
freez
dryer
dissolv
ml
pbspe
centrifug
g
min
supernat
collect
result
intestin
lavag
store
c
prior
analysi
measur
antibodi
level
individu
anim
determin
duplic
enzym
link
immunosorb
assay
elisa
determin
serum
igg
intestin
iga
level
immun
mice
polystyren
microtitr
plate
costar
coat
overnight
c
l
gml
purifi
tgevantigen
carbon
buffer
ph
block
h
c
pb
contain
wv
bsa
coat
antigen
prepar
sucros
densiti
gradient
centrifug
describ
previous
plate
wash
three
time
pb
contain
tween
pbst
incub
l
mice
serum
dilut
intestin
lavag
sampl
h
c
wash
three
time
pbst
hrpconjug
goat
antimic
igg
iga
sigma
dilut
use
secondari
antibodi
incub
h
c
tetramethyl
benzidin
tmb
employ
substrat
min
incub
dark
reaction
stop
addit
l
h
moll
optic
densiti
nm
measur
elisa
micropl
reader
total
serum
igg
intestin
lavag
iga
specif
tgev
repres
optic
densiti
data
analyz
use
onesid
student
test
differ
consid
statist
signific
p
purdu
tfi
strain
indic
amino
termin
half
glycoprotein
highli
conserv
among
differ
tgev
strain
gene
fragment
incorpor
vector
recombin
plasmid
pvax
detect
restrict
analysi
pcr
fig
express
pvax
demonstr
indirect
immunofluoresc
assay
cytoplasm
fluoresc
observ
cell
transfect
pvax
fig
parent
vector
fig
test
whether
attenu
typhimurium
potenti
deliv
tgev
dna
vaccin
apc
vitro
mous
primari
periton
macrophag
infect
attenu
typhimurium
pvax
harbour
tgev
gene
fifti
hour
infect
express
gene
macrophag
detect
ifa
cytoplasm
fluoresc
observ
cell
infect
pvax
fig
wherea
fluoresc
detect
cell
infect
attenu
typhimurium
pvax
harbour
empti
vector
fig
payer
patch
mainli
colon
site
attenu
typhimurium
import
immunolog
relev
site
context
mucos
respons
test
deliveri
tgev
dna
vaccin
vivo
use
attenu
salmonella
transgen
vehicl
total
cellular
rna
isol
mice
payer
patch
day
inocul
attenu
typhimurium
pvax
transcript
tgev
gene
analyz
rtpcr
shown
fig
dna
fragment
bp
amplifi
rna
mice
immun
pvax
meanwhil
dna
fragment
amplifi
rna
prior
revers
transcript
primer
rna
control
mice
immun
pvax
murin
dna
fragment
bp
amplifi
sampl
visibl
lesion
liver
spleen
observ
four
week
observ
period
kinet
colon
persist
bacteria
vivo
investig
bacteria
could
isol
liver
spleen
differ
dosag
group
week
postinocul
eventu
elimin
liver
spleen
four
week
postinocul
fig
pcr
enzym
digest
reveal
constant
presenc
gene
recov
bacteri
isol
abil
recombin
typhimurium
induc
mucos
immun
respons
determin
measur
level
iga
antibodi
tgev
intestin
lavag
sampl
shown
fig
recombin
typhimurium
induc
detect
iga
antibodi
tgev
ag
mice
rapidli
week
postvaccin
consider
enhanc
antibodi
titer
could
observ
group
b
c
receiv
pvax
dosag
cfu
respect
week
postimmun
addit
antibodi
level
group
c
significantli
higher
p
group
b
week
postvaccin
howev
lowlevel
antibodi
respons
could
detect
mice
group
receiv
low
dose
cfu
strain
pvax
throughout
whole
experi
specif
antitgev
antibodi
detect
intestin
lavag
sampl
pvax
group
group
pb
group
group
e
experi
abil
recombin
typhimurium
induc
humor
immun
respons
determin
measur
level
igg
antibodi
tgev
serum
sampl
shown
fig
none
group
detect
antibodi
respons
week
postvaccin
mice
group
b
c
receiv
pvax
dosag
cfu
respect
show
differ
level
antibodi
respons
experi
mice
group
b
c
show
higher
p
antitgev
elisa
antibodi
level
group
week
postimmun
week
postimmun
antibodi
titer
gener
group
b
c
reach
peak
meanwhil
antibodi
level
group
c
higher
p
group
b
howev
experi
mice
group
induc
neglig
antibodi
respons
week
postvaccin
detect
specif
antitgev
antibodi
pvax
group
group
pb
group
group
e
experi
pathogen
microorgan
either
restrict
mucos
membran
need
transit
across
mucos
barrier
earli
step
infect
thu
elicit
mucos
immun
respons
vaccin
highli
desir
potenti
approach
achiev
aim
use
attenu
salmonella
carrier
heterolog
antigen
report
demonstr
dna
vaccin
encod
ntermin
tgev
glycoprotein
deliv
attenu
typhimurium
simpl
potent
vaccin
elicit
serum
igg
mucos
iga
antibodi
respons
tgev
also
demonstr
dosag
cfu
elicit
higher
antibodi
respons
cfu
gener
assum
cross
intestin
mucos
barrier
mainli
via
cell
larg
amount
attenu
typhimurium
carri
eukaryot
express
plasmid
taken
apc
local
lymphoid
tissu
like
payer
patch
phagocyt
bacteria
start
replic
die
possibl
due
metabol
attenu
result
releas
plasmid
vivo
transfect
infect
cell
turn
produc
antigen
studi
use
attenu
salmonella
vehicl
tgev
gene
eukaryot
express
plasmid
detect
express
gene
mous
periton
macrophag
ifa
vitro
transcript
gene
payer
patch
rtpcr
vivo
result
indic
immun
oral
attenu
typhimurium
abil
deliv
tgev
dna
vaccin
antigen
express
apc
safeti
prerequisit
use
live
bacteri
vaccin
carrier
attenu
typhimuriu
delet
mutat
aroa
gene
impair
abil
grow
cultur
macrophag
mammalian
tissu
safeti
studi
neither
death
side
effect
found
mice
postinocul
attenu
typhimurium
pvax
differ
dosag
cfu
cfu
cfu
bacteri
recov
liver
fig
endpoint
dilut
elisa
analysi
antitgev
igg
antibodi
murin
serum
immun
sixweekold
balbc
mice
intragastr
immun
three
time
twoweek
interv
pvax
dosag
group
group
b
group
c
cfu
per
mice
control
mice
group
receiv
cfu
pvax
group
e
mice
receiv
pb
neg
control
murin
serum
collect
week
postimmun
analyz
endpoint
dilut
elisa
assay
use
tgev
coat
antigen
absorb
measur
nm
autom
plate
reader
result
express
mean
n
number
xaxi
indic
week
postprimari
immun
spleen
differ
dosag
group
two
week
boost
indic
attenu
typhimurium
could
elimin
immun
system
complet
plasmid
deliveri
time
notic
one
week
boost
bacteri
separ
liver
spleen
differ
dosag
group
significantli
lower
one
week
first
inocul
indic
elimin
immun
system
bacteri
enhanc
increas
inocul
frequenc
result
indic
use
attenu
typhimurium
ideal
choic
deliveri
vector
dna
vaccin
oral
concern
safeti
livestock
live
bacteri
vector
offer
mani
potenti
clinic
advantag
stabl
easi
rel
inexpens
massproduct
also
abl
deliv
multipl
antigen
oral
deliveri
increas
safeti
eas
administr
addit
bacteria
natur
possess
immunostimulatori
molecul
lipopolysaccharid
lp
function
adjuv
stimul
immun
respons
furthermor
live
bacteri
vector
abl
induc
system
immun
respons
includ
humor
cellular
mucos
immun
pathogen
infect
compar
three
differ
dosag
dna
vaccin
deliv
attenu
typhimurium
pvax
found
immunogen
tgev
dna
vaccin
highli
depend
dosag
attenu
bacteria
use
oral
administr
deliveri
dna
vaccin
low
dosag
cfu
elicit
weak
antitgev
igg
iga
antibodi
experi
vaccin
dosag
increas
cfu
igg
iga
antibodi
level
enhanc
meanwhil
highest
antibodi
respons
detect
week
postvaccin
vaccin
dosag
increas
cfu
summari
studi
provid
preliminari
evid
attenu
typhimurium
strain
util
oral
deliveri
vector
tgev
dna
vaccin
target
gene
could
express
vitro
also
vivo
develop
specif
humor
mucos
immun
respons
tgev
although
data
preliminari
ultim
tgev
vaccin
may
requir
incorpor
tgev
antigen
togeth
costimulatori
molecul
immunomodulatori
cytokin
attenu
typhimurium
may
adequ
deliveri
system
test
experi
dna
vaccin
tgev
obtain
maximum
immun
respons
